Hypoxia Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- 

https://shorturl.at/iTO13

Global Hypoxia Treatment Market reached US$ 77.6 million in 2022 and is expected to reach US$ 134.3 million by 2030 growing with a CAGR of 7.2% during the forecast period 2024-2031.

Hypoxia treatment refers to medical interventions aimed at increasing oxygen levels in the body when tissues are deprived of adequate oxygen. Common treatments include supplemental oxygen therapy, mechanical ventilation, and medications to improve oxygen delivery. The approach depends on the underlying cause, such as respiratory diseases, high altitude, or circulatory issues. Early treatment is crucial to prevent severe complications and organ damage.

List of the Key Players in the Hypoxia Treatment Market:

CASI Pharmaceuticals Inc., Aileron Therapeutics, Inc., Lupin Pharmaceuticals, Inc., PharmaShots, Hancock Medical Inc., Hamilton Company, Spotlight Labs, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., and Merck & Co among others.

Industry Development:

On February 1, 2023, GSK announced that Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), received approval from the U.S. Food and Drug Administration (FDA) for the once-daily treatment of anemia due to chronic kidney disease (CKD) in adults undergoing dialysis for at least four months. Jesduvroq marks the first innovative anemia treatment in over 30 years and is the only HIF-PHI approved in the U.S., offering a convenient oral option for CKD patients on dialysis.

On June 20, 2023, Akebia Therapeutics, Inc. announced that Swissmedic, the Swiss Agency for Therapeutic Products, granted marketing authorization for Vafseo (vadadustat), an oral HIF-PH inhibitor for treating symptomatic anemia associated with CKD in adults on chronic maintenance dialysis. The approval is based on clinical data from a development program involving over 7,500 patients, including a global Phase 3 trial evaluating vadadustat for anemia management in dialysis-dependent CKD patients.

Growth Forecast Projected:

The Global Hypoxia Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Hypoxia Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Hypoxia Treatment Market:

By Type: Hypoxic Hypoxia, Hypemic Hypoxic, Histotoxic Hypoxia, Stagnant Hypoxia

By Disease Type: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, Others

By End Users: Hospitals, Specialty Clinics, Others

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com